16 January 2008: CM&D Pharma and Natreon Inc announce the incorporation of Puredel Ltd to develop oral insulin Chertsey, UK January 16, 2008. CM&D Pharma Limited (CM&D), the European niche specialty company, today announced the incorporation of Puredel Ltd (Puredel), a newly formed joint venture aimed at developing Ossulin™ (oral insulin) and other targeted release compounds. Puredel is a newly formed joint venture with USA-based Natreon Inc., and plans to develop targeted release products based on Natreon’s proprietary delivery platform, NATSOM®. This technology uses a series of natural compounds to allow large molecular weight molecules to be absorbed through the gastrointestinal tract. Puredel will focus its initial efforts on the development of Ossulin, which has shown promising results in preliminary animal and human studies. Puredel will also explore other target molecules which are currently injected, and whose oral administration would greatly improve patient convenience and compliance. Natreon’s R&D staff and facilities in the United States and India will be committed to the success of Puredel. Puredel will coordinate the product development of Ossulin up to proof of clinical efficacy, drawing on its extensive network of scientific experts in Europe and North America. Lucien Hernandez, Natreon’s President and CEO said: “We have invested ten years in the development of the NATSOM® technology and intellectual property. By leveraging CM&D’s regulatory and scientific expertise, we can move swiftly and effectively to the next level of commercial development and maximize the enormous potential of this technology.” Danilo Casadei Massari, Corporate Development Director for CM&D, said: “The incorporation of Puredel marks a key point in the strategy of CM&D, adding yet another therapeutic innovation that could benefit millions of patients by connecting innovative science to traditional medicine.” Ends Note to Editors About CM&D Pharma Ltd CM&D Pharma Limited is a European niche specialty company founded in 2007. CM&D plans to become one of the few pan-European pharmaceutical companies targeting specialists in the five major European markets (France, Germany, Italy, Spain and the UK) with its own commercial organisation. It is establishing its own niche product and technology platform for in-house development, and will operate through a unique model of concerted marketing and development. About Natreon Inc With US headquarters in New Brunswick, New Jersey and a research centre in Kolkata, India, Natreon develops and markets functional food ingredients protected by intellectual property and proven by clinical and safety studies. Natreon’s research and development team includes seven PhD researchers and seven PhD candidates, working under the leadership of Dr. Shibnath Ghosal, a world renowned natural product scientist. For further information please contact Stephen Appelbee, CM&D CEO: +44 1932 796083 appelbee@cmdpharmaltd.com Lucien Hernandez, Natreon President & CEO +1-732-296-1080 lucien@natreoninc.com www.cmdpharmaltd.com www.natreoninc.com Ossulin™ is a trademark of CM&D Pharma Limited NATSOM®, is a trademark of Natreon Inc > Back